Acta Ophthalmologica最新文献

{"title":"Longitudinal progression of retinal nonperfusion in clinically stable diabetic retinopathy.","authors":"Stela Vujosevic, Sofia Ginelli, Alessandra Cernuschi, Celeste Limoli, Gabriele Piccoli, Elena Tagliabue, Emanuele Torti, Paolo Nucci, Paolo S Silva","doi":"10.1111/aos.70223","DOIUrl":"https://doi.org/10.1111/aos.70223","url":null,"abstract":"<p><strong>Purpose: </strong>To longitudinally assess and quantify changes in retinal nonperfusion (NP) in clinically stable diabetic retinopathy (DR) using ultra-widefield fluorescein angiography (UWF-FA) and optical coherence tomography angiography (OCTA).</p><p><strong>Methods: </strong>Fifty-one eyes from thirty-three patients were followed for a mean of 15.9 ± 11.4 months. Retinal NP was quantified on UWF-FA by a central reading centre using the nonperfusion index (NPI) for the posterior pole (NPI_PP), mid-periphery (NPI_MP) and far periphery (NPI_FP). OCTA metrics were analysed using ImageJ (Version 1.53, the National Institutes of Health, Bethesda, MD, USA) and MatLab (Version 2024a, MathWorks, Natick, MA).</p><p><strong>Results: </strong>Best-corrected visual acuity (BCVA) decreased with increasing DR severity (p = 0.0157). Peripheral NPI significantly increased over time (NPI_MP p = 0.007; NPI_FP p = 0.0007), particularly in moderate (NPI_FP p = 0.043) and severe NPDR (NPI_MP p = 0.041; NPI_FP p = 0.004). NPI values were consistently higher in severe NPDR and PDR than in moderate NPDR (all p < 0.0001). OCTA metrics remained stable longitudinally but were larger in advanced DR stages (p < 0.05).</p><p><strong>Conclusions: </strong>Peripheral NP, as quantified by NPI on UWF-FA, progresses over time despite apparent clinical stability of DR. In contrast, macular OCTA parameters remain unchanged. These findings suggest that peripheral iscahemic changes may occur earlier than detectable macular microvascular alterations and support the potential role of NPI as a quantitative imaging marker of retinal ischemia in DR.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accelerated biological ageing is associated with a large drusen burden.","authors":"Marie Ørskov, Lasse J Cehofski, Carsten Faber, Paolo Forte, Michael S Hansen, Danson V Muttuvelu, Siar Niazi, Marianne G Schou, Noreddin Shekho, Gregor S Reiter, Tor P Utheim, Anna S Vergmann, Yousif Subhi","doi":"10.1111/aos.70237","DOIUrl":"https://doi.org/10.1111/aos.70237","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the association between accelerated biological ageing, measured by Phenotypic Age (PhenoAge) and PhenoAge Acceleration (PhenoAgeAccel), and features of early and intermediate age-related macular degeneration (AMD) in a population-based cohort.</p><p><strong>Methods: </strong>This cross-sectional study used data from the National Health and Nutrition Examination Survey. Biological age was estimated using the PhenoAge algorithm, a composite of routine blood biomarkers and chronological age, and PhenoAgeAccel was defined as the residual from regression of PhenoAge on chronological age. Retinal outcomes were drusen ≥500 μm (primary outcome), drusen ≥125 μm and pigmentary abnormalities. Associations were evaluated using logistic regression adjusted for biological sex, race/ethnicity, smoking, body mass index and diabetes.</p><p><strong>Results: </strong>A total of 5322 participants were included (mean age 59.4 ± 12.4 years; 50.4% female). Drusen ≥500 μm were present in 4.1%, drusen ≥125 μm in 10.2% and pigmentary abnormalities in 5.6%. PhenoAgeAccel > + 3 years was associated with higher odds of drusen ≥500 μm (OR: 1.56, 95%CI: 1.07-2.27, p = 0.022), whereas no association was observed for <-3 years. Each 1-year increase in PhenoAgeAccel was associated with higher odds of drusen ≥500 μm (OR: 1.02, 95%CI: 1.00-1.04, p = 0.022). PhenoAgeAccel > + 3 years was also associated with drusen ≥125 μm (OR: 1.29, 95%CI: 1.00-1.65, p = 0.049), but not with pigmentary abnormalities.</p><p><strong>Conclusion: </strong>Accelerated biological ageing was associated with increased drusen burden, but not pigmentary abnormalities, suggesting that early structural features of AMD may reflect broader systemic ageing processes.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148966079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neovascular glaucoma at a tertiary Centre in Finland, 2008-2024: A retrospective cohort study.","authors":"Gilbert Simons, Mikael von Fersen, Paula Summanen, Mika Harju","doi":"10.1111/aos.70236","DOIUrl":"https://doi.org/10.1111/aos.70236","url":null,"abstract":"<p><strong>Purpose: </strong>Neovascular glaucoma (NVG) is a refractory secondary glaucoma, yet longitudinal outcome data remain limited. This study reports its aetiologies, treatments and outcomes.</p><p><strong>Methods: </strong>Patients with NVG were identified through electronic medical record review. Inclusion required documented rubeosis of the iris and/or anterior chamber angle, an intraocular pressure (IOP) ≥25 mmHg, diagnosis during 2008-2024, and follow-up at Helsinki University Hospital. Baseline data and all follow-up visits were included.</p><p><strong>Results: </strong>Of 919 patients identified, 626 met inclusion criteria, with a median follow-up of 24 months. The estimated NVG incidence was 2.2/100000/year. The most common aetiology was central retinal vein occlusion (CRVO; 45%), followed by diabetic retinopathy (DR; 14%), central retinal artery occlusion (CRAO; 11%) and ocular ischaemic syndrome (8%). Half of the patients had hand motion vision or worse at baseline, with 18% at no light perception (NLP). At 5 years, 14% had decimal 0.1 vision or better. Visual outcomes differed by aetiology, with median time to NLP ranging from 1.6 (CRAO) to 9.1 (DR) years (log-rank p = 0.002). Median baseline IOP was 40 mmHg, decreasing to 20 mmHg by 1 year. Ocular pain fell from 43% at baseline to 11% at last follow-up. Structural eye loss (e.g. enucleation or phthisis) occurred in 3% by 5 years.</p><p><strong>Conclusion: </strong>The estimated NVG incidence was lower than previously reported elsewhere. Unlike other cohorts where DR predominates, CRVO was the most common aetiology and visual prognosis was strongly aetiology-dependent. Glaucoma drainage device surgery reached 8% at 3 years, despite the severity and refractory nature of NVG.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of the PAUL® glaucoma implant for secondary glaucoma.","authors":"Carolin Deubel, Benjamin Aretz, Wolfgang Walz, Michael Petrak, Frank G Holz, Raffael Liegl, Karl Mercieca, Constance Liegl","doi":"10.1111/aos.70209","DOIUrl":"https://doi.org/10.1111/aos.70209","url":null,"abstract":"<p><strong>Purpose: </strong>Secondary glaucoma encompasses a broad spectrum of disease entities arising from diverse ocular pathologies and is often refractory to conventional treatment. Glaucoma drainage devices (GDDs) have therefore become an important surgical option. This study evaluates the efficacy and safety of the PAUL® Glaucoma Implant (PGI) across a broad spectrum of secondary glaucoma types.</p><p><strong>Methods: </strong>This retrospective observational cohort study included 96 eyes from 92 patients who underwent PGI implantation for secondary glaucoma between April 2021 and September 2024, with a minimum follow-up of 12 months. Secondary glaucomas were categorized into neovascular, uveitic, post-vitrectomy, traumatic and other types. Surgical success was defined according to World Glaucoma Association intraocular pressure (IOP) thresholds (≤21, ≤18, ≤15, and ≤12 mmHg), with failure defined by IOP above threshold, hypotony-related complications, need for further glaucoma surgery, or device explantation.</p><p><strong>Results: </strong>At one year, 83% of eyes achieved an IOP ≤21 mmHg, with 42% maintaining this level without topical medication. Success rates declined with stricter IOP targets but did not differ significantly among secondary glaucoma subtypes. Mean IOP decreased significantly from 28.0 mmHg preoperatively to 13.6 mmHg at 12 months, corresponding to an average reduction of approximately 51%, and remained stable during long-term follow-up. Visual acuity and visual field parameters remained largely stable. Postoperative complications occurred in 26% of eyes and were predominantly transient; no intraoperative complications were observed. Removal of the intraluminal Prolene stent was associated with further IOP reduction without subtype-specific differences.</p><p><strong>Conclusion: </strong>The PGI was associated with effective and sustained IOP reduction across a heterogeneous population of secondary glaucoma, with an acceptable complication profile in this retrospective cohort. These findings support the PGI as a useful surgical option for complex secondary glaucoma, although controlled comparative studies are needed to define its relative role among established GDDs.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148917800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of faricimab and high-dose aflibercept on treatment demand in a tertiary ophthalmic centre in Norway.","authors":"Thea Blix, Jacopo Francesco Taraldsrud Løkken, Leif Arthur Steffensen, Erik Magnus Sæther, Yngvil Solheim Husum, Eva Meling Ødegaard, Ragnheidur Bragadottir, Morten Carstens Moe, Øystein Kalsnes Jørstad","doi":"10.1111/aos.70240","DOIUrl":"https://doi.org/10.1111/aos.70240","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the impact of introducing faricimab and high-dose aflibercept on intravitreal injection (IVI) demand and treatment costs for retinal diseases in a large tertiary retina centre.</p><p><strong>Methods: </strong>This retrospective longitudinal registry study included all anti-VEGF treatment episodes at Oslo University Hospital, Norway, between 2021 and 2025. Annual injection volumes, treatment patterns, and costs were assessed following the introduction of faricimab (2023) and high-dose aflibercept (2025). High-dose aflibercept was generally administered at 50 μL (5.7 mg). Costs components were estimated using a health-economic model.</p><p><strong>Results: </strong>A total of 142 960 treatment episodes comprising 169 700 IVIs in 7865 patients (mean age 75.5 years, 56.6% female) were included. Macular degeneration was the most common diagnosis. Treated patients increased from 4148 in 2021 to 4982 in 2025. Injections increased from 31 780 in 2021 to a peak of 35 508 in 2024 before declining to 33 696 in 2025, while mean injections per patient decreased from 7.7 to 6.8. Following its introduction in 2023, faricimab became the most used agent. Off-label bevacizumab proportion decreased from 50.6% in 2021 to 30.0% in 2025. Mean treatment cost per patient increased from NOK 38029 in 2021 to NOK 40187 in 2025 (+5.7%), while total treatment costs increased from NOK 158 million to NOK 200 million (+26.9%).</p><p><strong>Conclusions: </strong>The introduction of faricimab and high-dose aflibercept was associated with reduced per-patient treatment intensity, while the treated population continued to increase. Longer-acting anti-VEGF drugs may reduce pressure on retinal services by lowering injection frequency; however, their introduction was associated with higher overall costs.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148904542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of the relevancy of nutritional knowledge and self-perceived nutrition competency of the UK Optometric Workforce.","authors":"Duane Mellor, Nicola J Milhench, Rebekka Heitmar","doi":"10.1111/aos.70221","DOIUrl":"https://doi.org/10.1111/aos.70221","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigated the self-perceived competence, knowledge, confidence and attitudes of the UK optometric workforce with regard to nutritional advice for patients.</p><p><strong>Methods: </strong>A validated questionnaire (NUTrition COMPetence) was used to survey the optometric workforce, which was adapted to UK optometric practice and nutritional guidelines. Distribution of the questionnaire was conducted online via social media, local optical councils, and personal contacts and sent to a random sample of members of the College of Optometrists UK. To better understand the sample, further information on educational background, years in practice and current roles were collected.</p><p><strong>Results: </strong>Two hundred and sixty individuals completed the questionnaire, of which 238 identified as GOC registered optometrists, with the majority working in a community setting (n = 189). Self-perceived confidence in nutrition knowledge was [mean score (SD) 17.19 (±4.11) out of a maximum of 35 points], nutrition skills [mean score (SD) 23.73 (±7.80) out of a maximum count of 55], nutrition related counselling and communication [mean score (SD) 26.06 (±6.82) out of a maximum of 45 points]. Attitudes towards nutrition care scored highest with 31.33 (±6.06) out of 40 and was rated highest out of all constructs. Higher qualifications were associated with increased levels of self-reported confidence and communication of nutrition information (p = 0.015).</p><p><strong>Conclusions: </strong>UK optometrists have a very positive attitude towards providing nutritional care. However, there is a lack of training which impacts confidence and ultimately patient advice. Within the current framework of the UK National Health Service and its focus to make every contact count, it is paramount to implement more nutritional training.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minocycline and bone marrow-derived mononuclear cells as potential therapeutics for hereditary retinal degenerations.","authors":"Alba Videla-Ristol, Ana Martínez-Vacas, David García-Bernal, Manuel Vidal-Sanz, María Paz Villegas-Pérez, Diego García-Ayuso, Johnny Di Pierdomenico","doi":"10.1111/aos.70108","DOIUrl":"10.1111/aos.70108","url":null,"abstract":"<p><strong>Purpose: </strong>To assess in Royal College of Surgeons (RCS) rats if the combination of two previously documented neuroprotective strategies: minocycline administration and bone marrow-derived mononuclear cells (BM-MNCs) intravitreal transplantation, offers enhanced neuroprotection compared with each treatment alone.</p><p><strong>Methods: </strong>Forty-eight homozygous pigmented RCS rats were divided into four groups: control, intravitreal BM-MNC transplantation, systemic minocycline treatment or combined therapy. Treatments were administered at postnatal day (P) 27-28. Animals were evaluated in vivo by spectral domain optical coherence tomography (SD-OCT) at P28, P35 and P51. Retinal sections were analysed for photoreceptor survival (outer nuclear layer [ONL] cell counts), synaptic preservation (Bassoon immunoreactivity), microglial activation (Iba-1+ cells) and macroglial reactivity (glial fibrillary acidic protein [GFAP] expression).</p><p><strong>Results: </strong>Both BM-MNC and minocycline monotherapies significantly preserved total and outer retinal thicknesses and increased ONL nuclei counts compared with controls. Combined treatment yielded superior protection at both P35 and P51. Minocycline alone or in combination significantly reduced microglial cell activation, while BM-MNCs alone or in combination significantly reduced GFAP expression. Synaptic integrity in the outer plexiform layer, assessed via Bassoon labelling, was significantly better preserved in treated animals, with the highest levels observed in the combined therapy group.</p><p><strong>Conclusions: </strong>Minocycline and BM-MNCs provide complementary neuroprotective effects in the RCS rat model. While minocycline reduces microglial activation, BM-MNCs modulate macroglial response. Their combination enhances photoreceptor survival and synaptic preservation more effectively than either treatment alone. These findings support the therapeutic potential of combining pharmacological and cell-based interventions in hereditary retinal degenerations.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":"e671-e685"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13460373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147429966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced rates of intraocular surgeries in anterior uveitis.","authors":"Sanna Leinonen, Rita Palviainen","doi":"10.1111/aos.70129","DOIUrl":"10.1111/aos.70129","url":null,"abstract":"","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":"e720-e721"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13460379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence after treat-and-extend suspension in neovascular age-related macular degeneration: A real-world analysis by macular neovascularization subtype.","authors":"Geoffrey Zeender, Amandine Moulin, Pauline Rizzuto, Sandra Elbany, Pierre Gascon, Kevin Allaix, Audrey Feldman, Flore De Bats, Benjamin Wolff, Emmanuelle Bassouamina-Kinanga, Corinne Dot, Laurent Kodjikian, Thibaud Mathis","doi":"10.1111/aos.70132","DOIUrl":"10.1111/aos.70132","url":null,"abstract":"","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":"e718-e719"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13460352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revised Swedish visual field standards for a driver's licence: Threshold perimetry as a predictor of eligibility according to the current Swedish and current Norwegian suprathreshold standards.","authors":"Wid Saadi, Tomas Bro, Susanna Sagerfors","doi":"10.1111/aos.70111","DOIUrl":"10.1111/aos.70111","url":null,"abstract":"<p><strong>Purpose: </strong>To explore whether threshold perimetry can predict fulfilment of the current Swedish and current Norwegian Esterman perimetry standards for Group 1 driver's licence, and differences in compliance between the former and current Swedish visual field standards.</p><p><strong>Methods: </strong>This study included perimetry examinations from individuals aged ≥18 years who underwent threshold perimetry (24-2 or 30-2) and binocular Esterman visual field testing on the same day during September 2010 to December 2022. Data were collected over 12 years from three Departments of Ophthalmology in Region Örebro County, Sweden. Threshold perimetry data were used to predict fulfilment of the current Swedish and current Norwegian Esterman visual field standards.</p><p><strong>Results: </strong>In all, 798 individuals were included. Altogether (33%) failed the Swedish visual field standards for a Group 1 driver's licence in the past; by comparison, a significantly smaller proportion would have failed the current Swedish standards today, (18%) (p < 0.001; McNemar's test). Threshold perimetry, if all test points within the central 20° had values of ≥10 dB, could predict compliance with a sensitivity of 89% and 88% and a specificity of 73% and 78% for the current Swedish and current Norwegian Esterman standards, respectively.</p><p><strong>Conclusion: </strong>Threshold perimetry may predict compliance with the current Swedish and current Norwegian Esterman visual field test standard for driving. A larger proportion of individuals may meet the current Swedish visual field standard for a Group 1 driver's licence compared with the former Swedish standard.</p>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":"e709-e717"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13460349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147372103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}